Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zeria Pharmaceutical Co., Ltd. (4559.T)
Tokyo, TK, JP
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural and industrial chemicals, and reagents in Japan and internationally. The company operates through Ethical Pharmaceuticals Business and Consumer Healthcare Business segments. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company also offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn’s disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia, and iron deficiency anemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; and non-steroidal anti-inflammatory ophthalmic solutions. In addition, it provides consumer healthcare products, such as nutritional health drugs, remedies for gastrointestinal diseases, western herbal medicines, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and food for specified health uses. Further, the company engages in insurance agency and real estate business. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was incorporated in 1955 and is headquartered in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.69% | +8.30% | +1.39% | +5.56% | +19.92% | +11.13% | +7.55% | -4.50% | +16.63% | +70.39% | +147.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.1% Q1'26: +11.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-14.9% Q1'26: +69.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+9.3% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+13.9% ★ Q1'26: +15.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+7.8% ★ Q1'26: +9.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.98× Q1'26: 1.69× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
61.01B
est: 70.50B (-13.5%)
|
62.48B
est: 63.00B (-0.8%)
|
64.86B
est: 67.00B (-3.2%)
|
64.58B
est: 68.70B (-6.0%)
|
61.82B
est: 62.00B (-0.3%)
|
60.44B
est: 62.85B (-3.8%)
|
52.76B
est: 56.50B (-6.6%)
|
59.53B
est: 60.50B (-1.6%)
|
68.38B
est: 68.10B (+0.4%)
|
75.73B
est: 75.70B (+0.0%)
|
87.31B
est: 86.50B (+0.9%)
|
88.00B
88.00B – 88.00B
+1.7% YoY
|
93.00B
93.00B – 93.00B
+5.7% YoY
|
98.00B
98.00B – 98.00B
+5.4% YoY
|
101.00B
101.00B – 101.00B
+3.1% YoY
|
| EBITDA |
5.39B
est: 14.45B (-62.7%)
|
7.68B
est: 12.91B (-40.5%)
|
8.34B
est: 13.73B (-39.3%)
|
8.67B
est: 14.08B (-38.4%)
|
7.47B
est: 12.70B (-41.2%)
|
7.95B
est: 12.88B (-38.2%)
|
7.91B
est: 11.58B (-31.7%)
|
11.77B
est: 12.40B (-5.1%)
|
15.16B
est: 13.95B (+8.7%)
|
17.27B
est: 15.50B (+11.4%)
|
19.75B
est: 21.30B (-7.3%)
|
21.67B
21.67B – 21.67B
+1.7% YoY
|
22.90B
22.90B – 22.90B
+5.7% YoY
|
24.13B
24.13B – 24.13B
+5.4% YoY
|
24.87B
24.87B – 24.87B
+3.1% YoY
|
| EBIT |
2.68B
est: 8.09B (-66.9%)
|
4.57B
est: 7.23B (-36.8%)
|
4.54B
est: 7.69B (-40.9%)
|
4.83B
est: 7.88B (-38.7%)
|
3.74B
est: 7.11B (-47.5%)
|
4.01B
est: 7.21B (-44.4%)
|
3.48B
est: 6.48B (-46.4%)
|
6.37B
est: 6.94B (-8.3%)
|
9.01B
est: 7.81B (+15.4%)
|
9.72B
est: 8.67B (+12.1%)
|
12.20B
est: 14.99B (-18.6%)
|
15.25B
15.25B – 15.25B
+1.7% YoY
|
16.12B
16.12B – 16.12B
+5.7% YoY
|
16.98B
16.98B – 16.98B
+5.4% YoY
|
17.50B
17.50B – 17.50B
+3.1% YoY
|
| Net Income |
2.56B
est: 5.23B (-51.1%)
|
3.51B
est: 2.87B (+22.6%)
|
3.54B
est: 3.55B (-0.2%)
|
4.16B
est: 3.27B (+27.1%)
|
3.45B
est: 2.89B (+19.5%)
|
2.93B
est: 3.11B (-5.9%)
|
3.14B
est: 3.36B (-6.4%)
|
3.96B
est: 3.82B (+3.8%)
|
6.20B
est: 6.67B (-7.1%)
|
7.73B
est: 8.50B (-9.0%)
|
9.94B
est: 9.00B (+10.4%)
|
7.50B
7.50B – 7.50B
-16.7% YoY
|
9.90B
9.90B – 9.90B
+32.0% YoY
|
10.80B
10.80B – 10.80B
+9.1% YoY
|
10.90B
10.90B – 10.90B
+0.9% YoY
|
| SGA |
20.96B
est: 37.52B (-44.1%)
|
31.40B
est: 33.52B (-6.3%)
|
33.69B
est: 35.65B (-5.5%)
|
34.07B
est: 36.56B (-6.8%)
|
33.50B
est: 32.99B (+1.5%)
|
33.44B
est: 33.45B (0.0%)
|
28.07B
est: 30.07B (-6.6%)
|
30.99B
est: 32.19B (-3.7%)
|
32.65B
est: 36.24B (-9.9%)
|
36.74B
est: 37.76B (-2.7%)
|
41.81B
est: 44.19B (-5.4%)
|
44.95B
44.95B – 44.95B
+1.7% YoY
|
47.51B
47.51B – 47.51B
+5.7% YoY
|
50.06B
50.06B – 50.06B
+5.4% YoY
|
51.60B
51.60B – 51.60B
+3.1% YoY
|
| EPS |
48.15
est: 118.60 (-59.4%)
|
66.15
est: 65.00 (+1.8%)
|
66.73
est: 80.60 (-17.2%)
|
80.72
est: 74.20 (+8.8%)
|
69.56
est: 65.60 (+6.0%)
|
62.62
est: 70.55 (-11.2%)
|
68.22
est: 76.20 (-10.5%)
|
87.76
est: 86.60 (+1.3%)
|
140.26
est: 151.35 (-7.3%)
|
175.39
est: 192.80 (-9.0%)
|
225.42
est: 204.20 (+10.4%)
|
170.10
170.10 – 170.10
-16.7% YoY
|
224.60
224.60 – 224.60
+32.0% YoY
|
245.00
245.00 – 245.00
+9.1% YoY
|
247.30
247.30 – 247.30
+0.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.07% | 262.6K | 0.58% |
| 2 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.05% | 159.6K | 0.31% |
| 3 | State Street SPDR S&P International Small Cap ETF GWX | 0.04% | 327.5K | 0.40% |
| 4 | iShares International Small-Cap Equity Factor ETF ISCF | 0.03% | 185.5K | 0.24% |
| 5 | iShares MSCI Japan Small-Cap ETF SCJ | 0.02% | 62.0K | 0.50% |
| 6 | WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc DXJD.SW | 0.02% | 235.9K | 0.45% |
| 7 | WisdomTree Japan Equity UCITS ETF - USD Acc DXJZ.L | 0.02% | 191.1K | 0.40% |
| 8 | WisdomTree Japan Equity UCITS ETF - EUR Hedged Acc DXJF.MI | 0.02% | 217.7K | 0.45% |
| 9 | WisdomTree Japan Equity UCITS ETF - GBP Hedged DXJP.L | 0.02% | 255.6K | 0.45% |
| 10 | WisdomTree Japan Equity UCITS ETF DXJ.L | 0.02% | 191.1K | 0.48% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hiroki Kato | Managing Executive Officer and GM of Asian Business, Planning Department & Business Development | — | male |
| Kazuhiro Akiba | Executive Officer & GM of Pharmaceutical Sales Division | — | — |
| Kenji Kusano | Executive Officer & GM of Consumer Healthcare Sales Division | — | — |
| Mitsuhiro Ibe | President, Chief Operating Officer & Representative Director | — | male |
| Mitsuru Iwai | Executive Officer & GM of Production & Logistics Headquarters | — | — |
| Sachiaki Ibe | Chairman & Chief Executive Officer | — | male |
| Toshiaki Kawagoe | Executive Officer and GM of Reliability Assurance Headquarters & Customer Relations Office | — | — |
| Yasuhisa Tanaka | Executive Officer and GM of Finance & Accounting Division | — | — |
| Yoshihiro Hiraga | Executive Officer and GM of Research & Development Headquarters, Licensing Office | — | male |
| Yuuki Okazawa | Managing Executive Officer, GM of Administration, Personnel, Legal & Compliance Dept. and Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4559.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
